Plant secondary metabolites in cancer chemotherapy: Where are we?

Current Pharmaceutical Biotechnology

Volumn 13, Issue 5, 2012, Pages 632-650

  Pereira, David M ^a   Valentão, Patrícia ^a   Correia da Silva, Georgina ^a,b   Teixeira, Natércia ^a,b   Andrade, Paula B ^a  

^a UNIVERSITY OF PORTO   (Portugal)

^b UNIVERSITY OF PORTO   (Portugal)

Author keywords

Cancer; Combretastatins; Plants secondary metabolites; Podophylotoxins and camptothecins; Taxanes; Vinca alkaloids

Indexed keywords

BELOTECAN; CABAZITAXEL; CAMPTOTHECIN DERIVATIVE; COMBRETASTATIN; COSITECAN; CURCUMIN; DIFLOMOTECAN; DOCETAXEL; EC 145; ETOPOPOS; ETOPOSIDE; EXATECAN; GIMATECAN; HYDRAVIN; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; IRINOTECAN; LAROTAXEL; NAVELBINE; ORTATAXEL; PACLITAXEL; PODOPHYLOTOXIN; PROTEIN KINASE; RUBITECAN; TAXANE DERIVATIVE; TAXOPREXIN; TENIPOSIDE; TOPOTECAN; TUBULIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VINBLASTINE; VINBLASTINE SULFATE; VINCA ALKALOID; VINCRISTINE; VINCRISTINE SULFATE; VINDESINE; VINFLUNINE;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; BIOTECHNOLOGY; BREAST CANCER; CANCER CHEMOTHERAPY; CLINICAL TRIAL; HODGKIN DISEASE; HUMAN; LEUKEMIA; LIVER CANCER; LUNG CANCER; LUNG NON SMALL CELL CANCER; LYMPHOMA; MEDICINAL PLANT; METABOLOMICS; MITOCHONDRION; MOLECULAR MECHANICS; NEUROTOXICITY; NONHUMAN; REVIEW; SPLEEN CANCER;

ANIMALS; ANTINEOPLASTIC AGENTS, PHYTOGENIC; CLINICAL TRIALS AS TOPIC; HUMANS; NEOPLASMS; PLANT EXTRACTS; PLANTS;

EMBRYOPHYTA; VINCA;

EID: 84860284321     PISSN: 13892010     EISSN: 18734316     Source Type: Journal    
DOI: 10.2174/138920112799857530     Document Type: Review

References (167)

1. Ferlay, J.; Shin, H.R.; Bray, F.; Forman, D.; Mathers, C.; Parkin, D.M. Cancer incidence and mortality worldwide in 2008. http://globocan.iarc.fr (accessed 06/07/2011).
2. Samuelsson, G., Drugs of natural orign: a textbook of pharmacognosy. Swedish Pharmaceutical Press: Stockholm, 2004.
3. Cragg, G.M.; Newman, D.J. Nature: a vital source of leads for anticancer drug development. Phytochem. Rev., 2009, 8, 313-331.
4. Kingston, D.G.I. Tubulin-interactive natural products as anticancer agents. J. Nat. Prod., 2009, 72, 507-515.
5. Costantino, L.; Barlocco, D. Privileged structures as leads in medicinal chemistry. Curr. Med. Chem., 2006, 13, 65-85.
6. Pereira, D.M.; Ferreres, F.; Oliveira, J.; Valentao, P.; Andrade, P.B.; Sottomayor, M. Targeted metabolite analysis of Catharanthus roseus and its biological potential. Food Chem. Toxicol., 2009, 47, 1349-54.
7. Pereira, D.M.; Ferreres, F.; Oliveira, J.M.; Gaspar, L.; Faria, J.; Valentao, P.; Sottomayor, M.; Andrade, P.B. Pharmacological effects of Catharanthus roseus root alkaloids in acetylcholinesterase inhibition and cholinergic neurotransmission. Phytomedicine, 2010, 17, 646-652.
8. Balunas, M.J.; Kinghorn, A.D. Drug discovery from medicinal plants. Life Sci., 2005, 78, 431-41.
9. German, J.B.; Roberts, M.A.; Watkins, S.M. Genomics and metabolomics as markers for the interaction of diet and health: Lessons from lipids. J. Nutr., 2003, 133, 2078s-2083s.
10. Pereira, D.M.; Valentão, P.; Ferreres, F.; Andrade, P.B. Metabolomic analysis of natural products. In Reviews In Pharmaceutical and Biomedical Analysis, Bentham: 2009.
11. Ferreres, F.; Pereira, D.M.; Gil-Izquierdo, A.; Valentao, P.; Botelho, J.; Mouga, T.; Andrade, P.B. HPLC-PAD-atmospheric pressure chemical ionization-MS metabolite profiling of cytotoxic carotenoids from the echinoderm Marthasterias glacialis (spiny sea-star). J. Sep. Sci., 2010, 33, 2250-2257.
12. Cuyckens, F.; Claeys, M. Mass spectrometry in the structural analysis of flavonoids. J. Mass Spectrom., 2004, 39, 1-15.
13. Krishnan, P.; Kruger, N.J.; Ratcliffe, R.G. Metabolite fingerprinting and profiling in plants using NMR. J. Exp. Bot., 2005, 56, 255-265.
14. Hanahan, D.; Weinberg, R.A. Hallmarks of cancer: The next generation. Cell, 2011, 144, 646-674.
15. Hacker, G. The morphology of apoptosis. Cell Tissue Res., 2000, 301, 5-17.
16. Dirsch, V.M.; Muller, I.M.; Eichhorst, S.T.; Pettit, G.R.; Kamano, Y.; Inoue, M.; Xu, J.P.; Ichihara, Y.; Wanner, G.; Vollmar, A.M. Cephalostatin 1 selectively triggers the release of Smac/DIABLO and subsequent apoptosis that is characterized by an increased density of the mitochondrial matrix. Cancer Res., 2003, 63, 8869-76.
17. Chipuk, J.E.; Moldoveanu, T.; Llambi, F.; Parsons, M.J.; Green, D.R. The BCL-2 family reunion. Mol. Cell, 2010, 37, 299-310.
18. Ashkenazi, A.; Herbst, R.S. To kill a tumor cell: the potential of proapoptotic receptor agonists. J. Clin. Invest., 2008, 118, 1979-1990.
19. Ricci, M.; El-Deiry, W. The Extrinsic Pathway of Apoptosis. In Apoptosis, Senescence, and Cancer, Gewirtz, D. A.; Holt, S. E.; Grant, S., Eds. Humana Press: 2007; pp 31-54.
20. Wajant, H. The Fas signaling pathway: More than a paradigm. Science, 2002, 296, 1635-1636.
21. Janmaat, M.L.; Rodriguez, J.A.; Jimeno, J.; Kruyt, F.A.E.; Giaccone, G. Kahalalide F induces necrosis-like cell death that involves depletion of ErbB3 and inhibition of Akt signaling. Mol. Pharmacol., 2005, 68, 502-510.
22. Golstein, P.; Kroemer, G. Cell death by necrosis: towards a molecular definition. Trends Biochem. Sci., 2007, 32, 37-43.
23. Lenardo, M.J.; McPhee, C.K.; Yu, L. Autophagic Cell Death. In Autophagy in Diesease and Clinical Applications, Klionsky, D. J. Ed. Academic Press: Oxford, 2009; Vol. 453.
24. Espert, L.; Denizot, M.; Grimaldi, M.; Robert-Hebmann, V.; Gay, B.; Varbanov, M.; Codogno, P.; Biard-Piechaczyk, M. Autophagy is involved in T cell death after binding of HIV-1 envelope proteins to CXCR4. J. Clin. Invest., 2006, 116, 2161-2172.
25. Yu, L.; Wan, F.Y.; Dutta, S.; Welsh, S.; Liu, Z.H.; Freundt, E.; Baehrecke, E.H.; Lenardo, M. Autophagic programmed cell death by selective catalase degradation. Proc. Natl. Acad. Sci. USA, 2006, 103, 4952-4957.
26. Law, B.Y.K.; Wang, M.F.; Ma, D.L.; Al-Mousa, F.; Michelangeli, F.; Cheng, S.H.; Ng, M.H.L.; To, K.F.; Mok, A.Y.F.; Ko, R.Y.Y.; Lam, S.K.; Chen, F.; Che, C.M.; Chiu, P.; Ko, B.C.B. Alisol B, a novel inhibitor of the sarcoplasmic/endoplasmic reticulum Ca2+ ATPase pump, induces autophagy, endoplasmic reticulum stress, and apoptosis. Mol. Cancer Ther., 2010, 9, 718-730.
27. Puissant, A.; Robert, G.; Fenouille, N.; Luciano, F.; Cassuto, J.P.; Raynaud, S.; Auberger, P. Resveratrol promotes autophagic cell death in chronic myelogenous leukemia cells via JNK-mediated p62/SQSTM1 expression and AMPK activation. Cancer Res., 2010, 70, 1042-1052.
28. Hung, J.Y.; Hsu, Y.L.; Li, C.T.; Ko, Y.C.; Ni, W.C.; Huang, M.S.; Kuo, P.L. 6-Shogaol, an active constituent of dietary ginger, induces autophagy by inhibiting the AKT/mTOR pathway in human non-small cell lung cancer A549 cells. J. Agr. Food Chem., 2009, 57, 9809-9816.
29. Pasquier, E.; Kavallaris, M. Microtubules: A dynamic target in cancer therapy. Iubmb. Life, 2008, 60, 165-170.
30. Calligaris, D.; Verdier-Pinard, P.; Devred, F.; Villard, C.; Braguer, D.; Lafitte, D. Microtubule targeting agents: From biophysics to proteomics. Cell Mol. Life Sci., 2010, 67, 1089-1104.
31. Bacher, G.; Beckers, T.; Emig, P.; Klenner, T.; Kutscher, B.; Nickel, B. New small-molecule tubulin inhibitors. Pure Appl. Chem., 2001, 73, 1459-1464.
32. Evans, P.C. Regulation of pro-inflammatory signalling networks by ubiquitin: identification of novel targets for anti-inflammatory drugs. Expert Rev. Mol. Med., 2005, 7, 1-19.
33. Coussens, L.M.; Werb, Z. Inflammation and cancer. Nature, 2002, 420, 860-867.
34. Greten, F.R.; Eckmann, L.; Greten, T.F.; Park, J.M.; Li, Z.W.; Egan, L.J.; Kagnoff, M.F.; Karin, M. IKK beta links inflammation and tumorigenesis in a mouse model of colitis-associated cancer. Cell, 2004, 118, 285-296.
35. Luedde, T.; Beraza, N.; Kotsikoris, V.; van Loo, G.; Nenci, A.; De Vos, R.; Roskams, T.; Trautwein, C.; Pasparakis, M. Deletion of NEMO/IKK gamma in liver parenchymal cells causes steatohepatitis and hepatocellular carcinoma. Cancer Cell, 2007, 11, 119-132.
36. Garg, A.; Aggarwal, B.B. Nuclear transcription factor-kappa B as a target for cancer drug development. Leukemia, 2002, 16, 1053-1068.
37. Sethi, G.; Sung, B.; Aggarwal, B.B. Nuclear factor-kB activation: From bench to bedside. Exp. Biol. Med., 2008, 233, 21-31.
38. Carmeliet, P.; Jain, R.K. Angiogenesis in cancer and other diseases. Nature, 2000, 407, 249-257.
39. Ferrara, N.; Hillan, K.J.; Gerber, H.P.; Novotny, W. Discovery and development of bevacizumab, an anti-VEGF antibody for treating cancer. Nat. Rev. Drug Discov., 2004, 3, 391-400.
40. Harris, A.L. Hypoxia - A key regulatory factor in tumour growth. Nat. Rev. Cancer, 2002, 2, 38-47.
41. Bos, R.; Zhong, H.; Hanrahan, C.F.; Mommers, E.C.M.; Semenza, G.L.; Pinedo, H.M.; Abeloff, M.D.; Simons, J.W.; van Diest, P.J.; van der Wall, E. Levels of hypoxia-inducible factor-1 alpha during breast carcinogenesis. J. Natl. Cancer Inst., 2001, 93, 309-314.
42. Fernand, V.E.; Losso, J.N.; Truax, R.E.; Villar, E.E.; Bwambok, D.K.; Fakayode, S.O.; Lowry, M.; Warner, I.M. Rhein inhibits angiogenesis and the viability of hormone-dependent and - independent cancer cells under normoxic or hypoxic conditions in vitro. Chem. Biol. Interact., 2011, 192, 220-32.
43. Carpini, J.D.; Karam, A.K.; Montgomery, L. Vascular endothelial growth factor and its relationship to the prognosis and treatment of breast, ovarian, and cervical cancer. Angiogenesis, 2010, 13, 43-58.
44. Holmes, K.; Roberts, O.L.; Thomas, A.M.; Cross, M.J. Vascular endothelial growth factor receptor-2: Structure, function, intracellular signalling and therapeutic inhibition. Cell Signal, 2007, 19, 2003-2012.
45. Folkman, J.; Bach, M.; Rowe, J.W.; Davidoff, F.; Lambert, P.; Hirsch, C.; Goldberg, A.; Hiatt, H.H.; Glass, J.; Henshaw, E. Tumor Angiogenesis - Therapeutic Implications. New Engl. J. Med., 1971, 285, 1182-&.
46. Masson-Gadais, B.; Houle, F.; Laferriere, J.; Huot, J. Integrin alpha(v)beta(3) requirement for VEGFR2-mediated activation of SAPK2/p38 and for Hsp90-dependent phosphorylation of focal adhesion kinase in endothelial cells activated by VEGF. Cell Stress Chaperon, 2003, 8, 37-52.
47. Holmqvist, K.; Cross, M.; Riley, D.; Welsh, M. The Shb adaptor protein causes Src-dependent cell spreading and activation of focal adhesion kinase in murine brain endothelial cells. Cell Signal., 2003, 15, 171-179.
48. Kitamura, T.; Asai, N.; Enomoto, A.; Maeda, K.; Kato, T.; Ishida, M.; Jiang, P.; Watanabe, T.; Usukura, J.; Kondo, T.; Costantini, F.; Murohara, T.; Takahashi, M. Regulation of VeGF-mediated angiogenesis by the Akt/PKB substrate Girdin. Nat. Cell Biol., 2008, 10, 329-U62.
49. Cohen, E.E.W.; Seiwert, T.Y. Targeting angiogenesis in head and neck cancer. Semin. Oncol., 2008, 35, 274-285.
50. Kim, E.S.; William, W.N.; Kies, M.S.; Fossella, F.V.; Liu, D.D.; Gladish, G.; Tse, W.H.; Lee, J.J.; Hong, W.K.; Lippman, S.M. Phase 2 study of carboplatin, docetaxel, and bevacizumab as frontline treatment for advanced nonsmall-cell lung cancer. Cancer, 2010, 116, 2401-2408.
51. Bocca, C.; Bozzo, F.; Cannito, S.; Colombatto, S.; Miglietta, A. CLA reduces breast cancer cell growth and invasion through ER alpha and PI3K/Akt pathways. Chem-Biol. Interact., 2010, 183, 187-193.
52. Fang, J.; Xia, C.; Cao, Z.X.; Zheng, J.Z.; Reed, E.; Jiang, B.H. Apigenin inhibits VEGF and HIF-1 expression via PI3K/AKT/ p70S6K1 and HDM2/p53 pathways. Faseb J, 2005, 19, 342-353.
53. Hasebe, Y.; Egawa, K.; Yamazaki, Y.; Kunimoto, S.; Hirai, Y.; Ida, Y.; Nose, K. Specific inhibition of hypoxia-inducible factor (HIF)-1 alpha activation and of vascular endothelial growth factor (VEGF) production by flavonoids. Biol. Pharm. Bull., 2003, 26, 1379-1383.
54. Zhang, X.; Song, Y.; Wu, Y.; Dong, Y.; Lai, L.; Zhang, J.; Lu, B.; Dai, F.; He, L.; Liu, M.; Yi, Z. Indirubin inhibits tumor growth by antitumor angiogenesis via blocking VEGFR2-mediated JAK/STAT3 signaling in endothelial cell. Int. J. Cancer, 2011, 129(10),2502-2511.
55. Gridelli, C.; Rossi, A.; Maione, P.; Rossi, E.; Castaldo, V.; Sacco, P.C.; Colantuoni, G. Vascular disrupting agents: a novel mechanism of action in the battle against non-small cell lung cancer. Oncologist, 2009, 14, 612-620.
56. Blume-Jensen, P.; Hunter, T. Oncogenic kinase signalling. Nature, 2001, 411, 355-365.
57. Weinstein, I.B.; Joe, A.K. Mechanisms of Disease: Oncogene addiction - A rationale for molecular targeting in cancer therapy. Nat. Clin. Pract. Oncol., 2006, 3, 448-457.
58. Zhang, J.M.; Yang, P.L.; Gray, N.S. Targeting cancer with small molecule kinase inhibitors. Nat. Rev. Cancer, 2009, 9, 28-39.
59. Fabbro, D.; Ruetz, S.; Buchdunger, E.; Cowan-Jacob, S.W.; Fendrich, G.; Liebetanz, J.; Mestan, J.; O'Reilly, T.; Traxler, P.; Chaudhuri, B.; Fretz, H.; Zimmermann, J.; Meyer, T.; Caravatti, G.; Furet, P.; Manley, P.W. Protein kinases as targets for anticancer agents: from inhibitors to useful drugs. Pharmacol. Therapeut., 2002, 93, 79-98.
60. Huang, Y.T.; Hwang, J.J.; Lee, P.P.; Ke, F.C.; Huang, J.H.; Huang, C.J.; Kandaswami, C.; Middleton, E.; Lee, M.T. Effects of luteolin and quercetin, inhibitors of tyrosine kinase, on cell growth and metastasis-associated properties in A431 cells overexpressing epidermal growth factor receptor. Br. J. Pharmacol., 1999, 128, 999-1010.
61. Joh, E.H.; Kim, D.H. Kalopanaxsaponin A ameliorates experimental colitis in mice by inhibiting IRAK-1 activation in the NF-κB and MAPK pathways. Br. J Pharmacol., 2011, 162, 1731-1742.
62. Konkimalla, V.B.; Efferth, T. Inhibition of epidermal growth factor receptor over-expressing cancer cells by the aphorphine-type isoquinoline alkaloid, dicentrine. Biochem. Pharmacol., 2010, 79, 1092-1099.
63. Dewick, P.M., Medicinal natural products: A biosynthetic approach. 3rd ed.; John Wiley & Sons Ltd: 2009.
64. Ngan, V.K.; Bellman, K.; Hill, B.T.; Wilson, L.; Jordan, M.A. Mechanism of mitotic block and inhibition of cell proliferation by the semisynthetic Vinca alkaloids vinorelbine and its newer derivative vinflunine. Mol. Pharmacol., 2001, 60, 225-32.
65. Wang, T.H.; Wang, H.S.; Ichijo, H.; Giannakakou, P.; Foster, J.S.; Fojo, T.; Wimalasena, J. Microtubule-interfering agents activate c- Jun N-terminal kinase stress-activated protein kinase through both ras and apoptosis signal-regulating kinase pathways. J. Biol. Chem., 1998, 273, 4928-4936.
66. Stone, A.A.; Chambers, T.C. Microtubule inhibitors elicit differential effects on MAP kinase (JNK, ERK, and p38) signaling pathways in human KB-3 carcinoma cells. Exp. Cell Res., 2000, 254, 110-119.
67. Bourgarel-Rey, V.; Savry, A.; Hua, G.; Carré, M.; Bressin, C.; Chacon, C.; Imbert, J.; Braguer, D.; Barra, Y. Transcriptional down-regulation of Bcl-2 by vinorelbine: Identification of a novel binding site of p53 on Bcl-2 promoter. Biochem. Pharmacol., 2009, 78, 1148-1156.
68. Hayakawa, A.; Kawamoto, Y.; Nakajima, H.; Sakai, J.I.; Takasawa, R.; Nakashima, I.; Magae, J.; Tanuma, S.I. Bid truncation mediated by caspases-3 and-9 in vinorelbine-induced apoptosis. Apoptosis, 2008, 13, 523-530.
69. Huang, Y.; Fang, Y.; Wu, J.; Dziadyk, J.M.; Zhu, X.; Sui, M.; Fan, W. Regulation of Vinca alkaloid-induced apoptosis by NFkappaB/ IkappaB pathway in human tumor cells. Mol. Cancer Ther., 2004, 3, 271-277.
70. Imbert, T.F. Discovery of podophyllotoxins. Biochimie, 1998, 80, 207-22.
71. Gordaliza, M.; Garcia, P.A.; del Corral, J.M.; Castro, M.A.; Gomez-Zurita, M.A. Podophyllotoxin: distribution, sources, applications and new cytotoxic derivatives. Toxicon, 2004, 44, 441-459.
72. Jackson, D.E.; Dewick, P.M. Aryltetralin lignans from Podophyllum hexandrum and Podophyllum peltatum. Phytochemistry, 1984, 23, 1147-1152.
73. Alam, M.A.; Naik, P.K. Impact of soil nutrients and environmental factors on podophyllotoxin content among 28 Podophyllum hexandrum populations of northwestern Himalayan region using linear and nonlinear approaches. Commun. Soil Sci. Plan, 2009, 40, 2485-2504.
74. Ayres, D.C.; Loike, J.D., Lignans - chemical, biological and clinical properties. Cambridge University Press: Cambridge, 1990.
75. Lin, J.H.; Castora, F.J. DNA topoisomerase II from mammalian mitochondria is inhibited by the antitumor drugs, m-AMSA and VM-26. Biochem. Biophys Res. Commun., 1991, 176, 690-677.
76. Robertson, J.D.; Gogvadze, V.; Zhivotovsky, B.; Orrenius, S. Distinct pathways for stimulation of cytochrome c release by etoposide. J. Biol. Chem., 2000, 275, 32438-32443.
77. Botta, B.; Delle Monache, G.; Misiti, D.; Vitali, A.; Zappia, G. Aryltetralin lignans: chemistry, pharmacology and biotransformations. Curr. Med. Chem., 2001, 8, 1363-1381.
78. Oostdam, A.; Mol, J.N.M.; Vanderplas, L.H.W. Establishment of hairy root cultures of Linum flavum producing the lignan 5- methoxypodophyllotoxin. Plant Cell Rep, 1993, 12, 474-477.
79. Itokawa, H.; Morris-Natschke, S.L.; Akiyama, T.; Lee, K.H. Plantderived natural product research aimed at new drug discovery. J. Nat. Med., 2008, 62, 263-280.
80. Wani, M.C.; Taylor, H.L.; Wall, M.E.; Coggon, P.; McPhail, A.T. Plant antitumor agents. VI. The isolation and structure of taxol, a novel antileukemic and antitumor agent from Taxus brevifolia. J. Am. Chem. Soc., 1971, 93, 2325-7.
81. Nicolaou, K.C.; Chen, J.S.; Dalby, S.M. From nature to the laboratory and into the clinic. Bioorgan. Med. Chem., 2009, 17, 2290-303.
82. Croteau, R.; Ketchum, R.E.; Long, R.M.; Kaspera, R.; Wildung, M.R. Taxol biosynthesis and molecular genetics. Phytochem. Rev., 2006, 5, 75-97.
83. Ibrahim, N.K.; Desai, N.; Legha, S.; Soon-Shiong, P.; Theriault, R.L.; Rivera, E.; Esmaeli, B.; Ring, S.E.; Bedikian, A.; Hortobagyi, G.N.; Ellerhorst, J.A. Phase I and pharmacokinetic study of ABI-007, a cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel. Clin. Cancer Res., 2002, 8, 1038-1044.
84. Kutuk, O.; Letai, A. Displacement of Bim by Bmf and Puma rather than increase in Bim level mediates paclitaxel-induced apoptosis in breast cancer cells. Cell Death Differ., 2010, 17, 1624-1635.
85. Wall, M.E.; Wani, M.C.; Cook, C.E.; Palmer, K.H.; Mcphail, A.T.; Sim, G.A. Plant antitumor agents.I. Isolation and structure of camptothecin a novel alkaloidal leukemia and tumor inhibitor from Camptotheca Acuminata. J. Am. Chem. Soc., 1966, 88, 3888-3890.
86. Giovanella, B.C.; Stehlin, J.S.; Wall, M.E.; Wani, M.C.; Nicholas, A.W.; Liu, L.F.; Silber, R.; Potmesil, M. DNA topoisomerase-I targeted chemotherapy of human colon cancer in xenografts. Science, 1989, 246, 1046-1048.
87. Pitot, H.C.; Knost, J.A.; Mahoney, M.R.; Kugler, J.; Krook, J.E.; Hatfield, A.K.; Sargent, D.J.; Goldberg, R.M. A north central cancer treatment group phase II trial of 9-aminocamptothecin in previously untreated patients with measurable metastatic colorectal carcinoma. Cancer, 2000, 89, 1699-1705.
88. Stehlin, J.S.; Giovanella, B.C.; Natelson, E.A.; De Ipolyi, P.D.; Coil, D.; Davis, B.; Wolk, D.; Wallace, P.; Trojacek, A. A study of 9-nitrocamptothecin (RFS-2000) in patients with advanced pancreatic cancer. Int. J. Oncol., 1999, 14, 821-831.
89. Venditto, V.J.; Simanek, E.E. Cancer therapies utilizing the camptothecins: A review of the in vivo literature. Mol. Pharmaceut., 2010, 7, 307-349.
90. Pizzolato, J.F.; Saltz, L.B. The camptothecins. Lancet, 2003, 361, 2235-2242.
91. Oberlies, N.H.; Kroll, D.J. Camptothecin and taxol: Historic achievements in natural products research. J. Nat. Prod., 2004, 67, 129-135.
92. Bredholt, T.; Dimba, E.A.O.; Hagland, H.R.; Wergeland, L.; Skavland, J.; Fossan, K.O.; Tronstad, K.J.; Johannessen, A.C.; Vintermyr, O.K.; Gjertsen, B.T. Camptothecin and khat (Catha edulis Forsk.) induced distinct cell death phenotypes involving modulation of c-FLIPL, Mcl-1, procaspase-8 and mitochondrial function in acute myeloid leukemia cell lines. Mol. Cancer, 2009, 8, 101.
93. Pettit, G.R.; Cragg, G.M.; Herald, D.L. Isolation and structure of combretastatin. Can. J. Chem., 1982, 60, 1374-1376.
94. Vitale, I.; Antoccia, A.; Cenciarelli, C.; Crateri, P.; Meschini, S.; Arancia, G.; Pisano, C.; Tanzarella, C. Combretastatin CA-4 and combretastatin derivative induce mitotic catastrophe dependent on spindle checkpoint and caspase-3 activation in non-small cell lung cancer cells. Apoptosis, 2007, 12, 155-66.
95. Nabha, S.M.; Mohammad, R.M.; Dandashi, M.H.; Coupaye- Gerard, B.; Aboukameel, A.; Pettit, G.R.; Al-Katib, A.M. Combretastatin-A4 prodrug induces mitotic catastrophe in chronic lymphocytic leukemia cell line independent of caspase activation and poly(ADP-ribose) polymerase cleavage. Clin. Cancer Res., 2002, 8, 2735-2741.
96. Kanthou, C.; Greco, O.; Stratford, A.; Cook, I.; Knight, R.; Benzakour, O.; Tozer, G. The tubulin-binding agent combretastatin A-4-phosphate arrests endothelial cells in mitosis and induces mitotic cell death. Am. J. Pathol., 2004, 165, 1401-1411.
97. Greene, L.M.; Nathwani, S.M.; Bright, S.A.; Fayne, D.; Croke, A.; Gagliardi, M.; McElligott, A.M.; O'Connor, L.; Carr, M.; Keely, N.O.; O'Boyle, N.M.; Carroll, P.; Sarkadi, B.; Conneally, E.; Lloyd, D.G.; Lawler, M.; Meegan, M.J.; Zisterer, D.M. The vascular targeting agent combretastatin-A4 and a novel cisrestricted beta-lactam analogue, CA-432,induce apoptosis in human chronic myeloid leukemia cells and ex vivo patient samples including those displaying Multidrug resistance. J. Pharmacol. Exp. Ther., 2010, 335, 302-313.
98. Lee, M.; Babu, B.; Lee, L.; Strobel, R.; Brockway, O.; Nickols, A.; Sjoholm, R.; Tzou, S.; Chavda, S.; Desta, D.; Fraley, G.; Siegfried, A.; Pennington, W.; Hartley, R.M.; Westbrook, C.; Mooberry, S.L.; Kiakos, K.; Hartley, J.A. Acetyl analogs of combretastatin A-4: Synthesis and biological studies. Bioorgan. Med. Chem., 2011, 19, 2359-2367.
99. Lee, M.; Brockway, O.; Dandavati, A.; Tzou, S.; Sjoholm, R.; Nickols, A.; Babu, B.; Chavda, S.; Satam, V.; Hartley, R.M.; Westbrook, C.; Mooberry, S.L.; Fraley, G. Design and synthesis of novel enhanced water soluble hydroxyethyl analogs of combretastatin A-4. Bioorgan. Med. Chem. Lett., 2011, 21, 2087-2091.
100. Lee, M.; Brockway, O.; Dandavati, A.; Tzou, S.; Sjoholm, R.; Satam, V.; Westbrook, C.; Mooberry, S.L.; Zeller, M.; Babu, B. A novel class of trans-methylpyrazoline analogs of combretastatins: Synthesis and in-vitro biological testing. Eur. J. Med. Chem., 2011, 46, 3099-3104.
101. Li, Y.W.; Liu, J.; Liu, N.; Shi, D.; Zhou, X.T.; Lv, J.G.; Zhu, J.; Zheng, C.H.; Zhou, Y.J. Imidazolone-amide bridges and their effects on tubulin polymerization in cis-locked vinylogous combretastatin-A4 analogues: Synthesis and biological evaluation. Bioorgan. Med. Chem., 2011, 19, 3579-3584.
102. Shan, Y.; Zhang, J.; Liu, Z.; Wang, M.; Dong, Y. Developments of combretastatin A-4 derivatives as anticancer agents. Curr. Med. Chem., 2011, 18, 523-538.
103. Chun, K.S.; Keum, Y.S.; Han, S.S.; Song, Y.S.; Kim, S.H.; Surh, Y.J. Curcumin inhibits phorbol ester-induced expression of cyclooxygenase-2 in mouse skin through suppression of extracellular signal-regulated kinase activity and NF-kappa B activation. Carcinogenesis, 2003, 24, 1515-1524.
104. Reuter, S.; Eifes, S.; Dicato, M.; Aggarwal, B.B.; Diederich, M. Modulation of anti-apoptotic and survival pathways by curcumin as a strategy to induce apoptosis in cancer cells. Biochem. Pharmacol., 2008, 76, 1340-1351.
105. Aggarwal, B.B.; Sundaram, C.; Malani, N.; Ichikawa, H. Curcumin: The Indian solid gold. Adv. Exp. Med. Biol., 2007, 595, 1-75.
106. Dhillon, N.; Aggarwal, B.B.; Newman, R.A.; Wolf, R.A.; Kunnumakkara, A.B.; Abbruzzese, J.L.; Ng, C.S.; Badmaev, V.; Kurzrock, R. Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin. Cancer Res., 2008, 14, 4491-4499.
107. Powell, R.G.; Weisleder, D.; Smith, C.R., Jr.; Rohwedder, W.K. Structures of harringtonine, isoharringtonine, and homoharringtonine. Tetrahedron Lett., 1970, 11, 815-818.
108. Yinjun, L.; Jie, J.; Weilai, X.; Xiangming, T. Homoharringtonine mediates myeloid cell apoptosis via upregulation of pro-apoptotic bax and inducing caspase-3-mediated cleavage of poly(ADPribose) polymerase (PARP). Am. J. Hematol., 2004, 76, 199-204.
109. Kamsteeg, M.; Rutherford, T.; Sapi, E.; Hanczaruk, B.; Shahabi, S.; Flick, M.; Brown, D.; Mor, G. Phenoxodiol-an isoflavone analog-induces apoptosis in chemoresistant ovarian cancer cells. Oncogene, 2003, 22, 2611-2620.
110. Yu, F.; Watts, R.N.; Zhang, X.D.; Borrow, J.M.; Hersey, P. Involvement of BH3-only proapoptotic proteins in mitochondrialdependent Phenoxodiol-induced apoptosis of human melanoma cells. Anti-Cancer Drug, 2006, 17, 1151-1161.
111. Aguero, M.F.; Venero, M.; Brown, D.M.; Smulson, M.E.; Espinoza, L.A. Phenoxodiol inhibits growth of metastatic prostate cancer cells. Prostate, 2010, 70, 1211-1221.
112. Nakao, H.; Senokuchi, K.; Umebayashi, C.; Kanemaru, K.; Masuda, T.; Oyama, Y.; Yonemori, S. Cytotoxic activity of maytanprine isolated from Maytenus diversifolia in human leukemia K562 cells. Biol. Pharm. Bull., 2004, 27, 1236-1240.
113. Cichewicz, R.H.; Kouzi, S.A. Chemistry, biological activity, and chemotherapeutic potential of betulinic acid for the prevention and treatment of cancer and HIV infection. Med. Res. Rev., 2004, 24, 90-114.
114. Fulda, S. Betulinic acid: a natural product with anticancer activity. Mol. Nutr. Food Res., 2009, 53, 140-146.
115. Pan, L.; Chai, H.; Kinghorn, A.D. The continuing search for antitumor agents from higher plants. Phytochem. Lett., 2010, 3, 1-8.
116. Taveira, M.; Pereira, D.M.; Sousa, C.; Ferreres, F.; Andrade, P.B.; Martins, A.; Pereira, J.A.; Valentao, P. In vitro cultures of Brassica oleracea L. var. costata DC: potential plant bioreactor for antioxidant phenolic compounds. J. Agric. Food Chem., 2009, 57, 1247-1252.
117. Sabater-Jara, A.B.; Tudela, L.R.; Lopez-Perez, A.J. In vitro culture of Taxus sp.: strategies to increase cell growth and taxoid production. Phytochem. Rev., 2010, 9, 343-356.
118. Wang, Z.Y.; Zhong, J.J. Repeated elicitation enhances taxane production in suspension cultures of Taxus chinensis in bioreactors. Biotechnol. Lett., 2002, 24, 445-448.
119. Karuppusamy, S. A review on trends in production of secondary metabolites from higher plants by in vitro tissue, organ and cell cultures. J. Med. Plants Res., 2009, 3, 1222-1239.
120. Fernandes, F.; Pereira, D.M.; de Pinho, P.G.; Valentão, P.; Pereira, J.A.; Bento, A.; Andrade, P.B. HS-SPME and GC/IT-MS applied to an alive system: Pieris brassicae fed with kale. Food Chem., 2010, 119, 1681-1693.
121. Laskaris, G.; Bounkhay, M.; Theodoridis, G.; van der Heijden, R.; Verpoorte, R.; Jaziri, M. Induction of geranylgeranyl diphosphate synthase activity and taxane accumulation in Taxus baccata cell cultures after elicitation by methyl jasmonate. Plant Sci., 1999, 147, 1-8.
122. Dong, H.D.; Zhong, J.J. Significant improvement of taxane production in suspension cultures of Taxus chinensis by combining elicitation with sucrose feed. Biochem. Eng. J., 2001, 8, 145-150.
123. Stierle, A.; Strobel, G.; Stierle, D.; Grothaus, P.; Bignami, G. The search for a taxol-producing microorganism among the endophytic fungi of the Pacific yew, Taxus brevifolia. J. Nat. Prod., 1995, 58, 1315-1324.
124. Eyberger, A.L.; Dondapati, R.; Porter, J.R. Endophyte fungal isolates from Podophyllum peltatum produce podophyllotoxin. J. Nat. Prod., 2006, 69, 1121-1124.
125. Puri, S.G.; Verma, V.; Amna, T.; Qazi, G.N.; Spiteller, M. An endophytic fungus from Nothapodytes foetida that produces camptothecin. J. Nat. Prod., 2005, 68, 1717-1719.
126. Senter, P.D. Potent antibody drug conjugates for cancer therapy. Curr. Opin. Chem. Biol., 2009, 13, 235-244.
127. Alley, S.C.; Okeley, N.M.; Senter, P.D. Antibody-drug conjugates: Targeted drug delivery for cancer. Curr. Opin. Chem. Biol., 2010, 14, 529-537.
128. Lambert, J.M. Antibody-maytansinoid conjugates: A new strategy for the treatment of cancer. Drug Future, 2010, 35, 471-480.
129. Li, J.; Sausville, E.A.; Klein, P.J.; Morgenstern, D.; Leamon, C.P.; Messmann, R.A.; LoRusso, P. Clinical pharmacokinetics and exposure-toxicity relationship of a folate-vinca alkaloid conjugate EC145 in cancer patients. J. Clin. Pharmacol., 2009, 49, 1467-1476.
130. Vlahov, I.R.; Santhapuram, H.K.R.; Kleindl, P.J.; Howard, S.J.; Stanford, K.M.; Leamon, C.P. Design and regioselective synthesis of a new generation of targeted chemotherapeutics. Part 1: EC145, a folic acid conjugate of desacetylvinblastine monohydrazide. Bioorg. Med. Chem. Lett., 2006, 16, 5093-5096.
131. Efferth, T. Cancer therapy with natural products and medicinal plants. Planta Med., 2010, 76, 1035-1036.
132. Dancey, J.; Steward, W.P. The role of vindesine in oncology - Recommendations after 10 years experience. Anti-Cancer Drug, 1995, 6, 625-636.
133. Joel, S. The comparative clinical pharmacology of vincristine and vindesine: Does vindesine offer any advantage in clinical use? Cancer Treat. Rev., 1995, 21, 513-525.
134. Saklani, A.; Kutty, S.K. Plant-derived compounds in clinical trials. Drug Discov. Today, 2008, 13, 161-171.
135. Lin, J.H.; Castora, F.J. DNA topoisomerase-Ii from mammalian mitochondria is inhibited by the antitumor drugs, M-Amsa and Vm-26. Biochem. Biophs. Res. Co., 1991, 176, 690-697.
136. Ramalingam, S.; Belani, C.P. Paclitaxel for non-small cell lung cancer. Expert Opin. Pharmacother., 2004, 5, 1771-1780.
137. Schiff, P.B.; Fant, J.; Horwitz, S.B. Promotion of microtubule assembly In vitro by taxol. Nature, 1979, 277, 665-667.
138. Davies, A.M.; Lara, P.N.; Mack, P.C.; Gandara, D.R. Docetaxel in non-small cell lung cancer: a review. Expert Opin. Pharmacother., 2003, 4, 553-565.
139. Metzger-Filho, O.; Moulin, C.; De Azambuja, E.; Ahamad, A. Larotaxel: broadening the road with new taxanes. Expert Opin. Investig. Drug, 2009, 18, 1183-1189.
140. Robert, F.; Harper, K.; Ackerman, J.; Gupta, S. A phase I study of larotaxel (XRP9881) administered in combination with carboplatin in chemotherapy-naïve patients with stage IIIB or stage IV nonsmall cell lung cancer. Cancer Chemother. Pharm., 2010, 65, 227-234.
141. Zatloukal, P.; Gervais, R.; Vansteenkiste, J.; Bosquee, L.; Sessa, C.; Brain, E.; Dansin, E.; Urban, T.; Dohollou, N.; Besenval, M.; Quoix, E. Randomized multicenter phase II study of larotaxel (XRP9881) in combination with cisplatin or gemcitabine as firstline chemotherapy in nonirradiable stage IIIB or stage IV nonsmall cell lung cancer. J. Thorac. Oncol., 2008, 3, 894-901.
142. Agarwal, N.; Sonpavde, G.; Sartor, O. Cabazitaxel for the treatment of castration-resistant prostate cancer. Future Oncol., 2011, 7, 15-24.
143. Dorff, T.B.; Quinn, D.I. Cabazitaxel in prostate cancer: Stretching a string. Lancet, 2010, 376, 1119-1120.
144. Fig Ii, W.D.; Figg Sr, W.D. Cabazitaxel: filling one of the gaps in the treatment of prostate cancer. Cancer Biol. Ther., 2010, 10, 1233-1234.
145. Homsi, J.; Bedikian, A.Y.; Kim, K.B.; Papadopoulos, N.E.; Hwu, W.J.; Mahoney, S.L.; Hwu, P. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in cutaneous and mucosal metastatic melanoma patients. Melanoma Res., 2009, 19, 238-242.
146. Homsi, J.; Bedikian, A.Y.; Papadopoulos, N.E.; Kim, K.B.; Hwu, W.J.; Mahoney, S.L.; Hwu, P. Phase 2 open-label study of weekly docosahexaenoic acid-paclitaxel in patients with metastatic uveal melanoma. Melanoma Res., 2010, 20, 507-510.
147. Jones, R.J.; Hawkins, R.E.; Eatock, M.M.; Ferry, D.R.; Eskens, F.A.L.M.; Wilke, H.; Evans, T.R.J. A phase II open-label study of DHA-paclitaxel (Taxoprexin) by 2-h intravenous infusion in previously untreated patients with locally advanced or metastatic gastric or oesophageal adenocarcinoma. Cancer Chemother. Pharm., 2008, 61, 435-441.
148. Spigel, D.R.; Greco, F.A. What is the role of novel taxanes in nonsmall-cell lung cancer? Clin. Lung Cancer, 2008, 9, S116-S121.
149. Cunningham, D.; Pyrhonen, S.; James, R.D.; Punt, C.J.A.; Hickish, T.F.; Heikkila, R.; Johannesen, T.B.; Starkhammar, H.; Topham, C.A.; Awad, L.; Jacques, C.; Herait, P. Randomised trial of irinotecan plus supportive care versus supportive care alone after fluorouracil failure for patients with metastatic colorectal cancer. Lancet, 1998, 352, 1413-1418.
150. Jeong, J.; Cho, B.C.; Sohn, J.H.; Choi, H.J.; Kim, S.H.; Lee, Y.J.; Jung, M.K.; Shin, S.J.; Park, M.S.; Kim, S.K.; Chang, J.; Kim, J.H. Belotecan for relapsing small-cell lung cancer patients initially treated with an irinotecan-containing chemotherapy: A phase II trial. Lung Cancer, 2010, 70, 77-81.
151. Kim, S.J.; Kim, J.S.; Kim, S.C.; Kim, Y.K.; Kang, J.Y.; Yoon, H.K.; Song, J.S.; Lee, S.H.; Moon, H.S.; Kim, J.W.; Kim, K.H.; Kim, C.H.; Shim, B.Y.; Kim, H.K. A multicenter phase II study of belotecan, new camptothecin analogue, in patients with previously untreated extensive stage disease small cell lung cancer. Lung Cancer, 2010, 68, 446-449.
152. Kim, Y.M.; Lee, S.W.; Kim, D.Y.; Kim, J.H.; Nam, J.H.; Kim, Y.T. The efficacy and toxicity of belotecan (CKD-602), a camptothecin analogue topoisomerase I inhibitor, in patients with recurrent or refractory epithelial ovarian cancer. J. Chemother., 2010, 22, 197-200.
153. Caponigro, F.; Cartenì, G.; Droz, J.P.; Milano, A.; Davis, W.B.; Pollard, P. Phase II study of rubitecan in recurrent or metastatic head and neck cancer. Cancer Chemother. Pharm., 2008, 62, 209-214.
154. Clark, J.W. Rubitecan. Expert Opin. Investig. Drug, 2006, 15, 71-79.
155. Patel, H.; Stoller, R.; Auber, M.; Potter, D.; Cai, C.; Zamboni, W.; Kiefer, G.; Matin, K.; Schmotzer, A.; Ramanathan, R.K. Phase II study of rubitecan, an oral camptothecin in patients with advanced colorectal cancer who have failed previous 5-fluorouracil based chemotherapy. Invest. New Drug, 2006, 24, 359-363.
156. Simon, G.R.; Lush, R.M.; Gump, J.; Tetteh, L.; Williams, C.; Cantor, A.; Antonia, S.; Garrett, C.; Rocha-Lima, C.; Fishman, M.; Sullivan, D.M.; Munster, P.N. Sequential oral 9-nitrocamptothecin and etoposide: A pharmacodynamic- and pharmacokinetic-based phase I trial. Mol. Cancer Ther., 2006, 5, 2130-2137.
157. Pecorelli, S.; Ray-Coquard, I.; Tredan, O.; Colombo, N.; Parma, G.; Tisi, G.; Katsaròs, D.; Lhommé, C.; Lissoni, A.A.; Vermorken, J.B.; du Bois, A.; Poveda, A.; Frigerio, L.; Barbieri, P.; Carminati, P.; Brienza, S.; Guastalla, J.P. Phase II of oral gimatecan in patients with recurrent epithelial ovarian, fallopian tube or peritoneal cancer, previously treated with platinum and taxanes. Ann. Oncol., 2010, 21, 759-765.
158. Sorbera, L.A.; Serradell, N.; Bolós, J.; Rosa, E.; Bozzo, J. Gimatecan - DNA-intercalating drug DNA topoisomerase I inhibitor. Drug Future, 2007, 32, 859-867.
159. Liao, Z.; Robey, R.W.; Guirouilh-Barbat, J.; To, K.K.W.; Polgar, O.; Bates, S.E.; Pommier, Y. Reduced expression of DNA topoisomerase I in SF295 human glioblastoma cells selected for resistance to homocamptothecin and diflomotecan. Mol. Pharmacol., 2008, 73, 490-497.
160. Scott, L.; Soepenberg, O.; Verweij, J.; de Jonge, M.J.A.; Th Planting, A.S.; McGovern, D.; Principe, P.; Obach, R.; Twelves, C. A multicentre phase I and pharmacokinetic study of BN80915 (diflomotecan) administered daily as a 20-min intravenous infusion for 5 days every 3 weeks to patients with advanced solid tumours. Ann. Oncol., 2007, 18, 569-575.
161. Abou-Alfa, G.K.; Rowinsky, E.K.; Patt, Y.Z.; Schwartz, G.K.; Kelsen, D.P.; Sharma, S.; Siegel, E.; Becerra, C.R.; Eckhardt, S.G.; Feit, K.; De Jager, R.; O'Reilly, E.M. A phase II study of intravenous exatecan administered daily for 5 days, every 3 weeks to patients with biliary tract cancers. Am. J. Clin. Oncol-Canc, 2005, 28, 334-339.
162. Reichardt, P.; Nielsen, O.S.; Bauer, S.; Hartmann, J.T.; Schöffski, P.; Christensen, T.B.; Pink, D.; Daugaard, S.; Marreaud, S.; Van Glabbeke, M.; Blay, J.Y. Exatecan in pretreated adult patients with advanced soft tissue sarcoma: Results of a phase II - study of the EORTC soft tissue and bone sarcoma group. Eur. J. Cancer, 2007, 43, 1017-1022.
163. Sharma, S.; Kemeny, N.; Schwartz, G.K.; Kelsen, D.; O'Reilly, E.; Ilson, D.; Coyle, J.; De Jager, R.L.; Ducharme, M.P.; Kleban, S.; Hollywood, E.; Saltz, L.B. Phase I study of topoisomerase I inhibitor exatecan mesylate (DX-8951f) given as weekly 24-hour infusions three of every four weeks. Clin. Cancer Res., 2001, 7, 3963-3970.
164. Daud, A.I.; Dawson, J.; Deconti, R.C.; Bicaku, E.; Marchion, D.; Bastien, S.; Hausheer Iii, F.A.; Lush, R.; Neuger, A.; Sullivan, D.M.; Munster, P.N. Potentiation of a topoisomerase i inhibitor, karenitecin, by the histone deacetylase inhibitor valproic acid in melanoma: translational and phase l/ll clinical trial. Clin. Cancer Res., 2009, 15, 2479-2487.
165. Kavanagh, J.J.; Sill, M.W.; Ramirez, P.T.; Warshal, D.; Pearl, M.L.; Morgan, M.A.; Mackey, D. Phase II multicenter open-label study of karenitecin in previously treated epithelial ovarian and primary peritoneal cancer: A gynecologic oncology group study. Int. J. Gynecol. Cancer, 2008, 18, 460-464.
166. Cassady, J.M.; Chan, K.K.; Floss, H.G.; Leistner, E. Recent developments in the maytansinoid antitumor agents. Chem. Pharm. Bull., 2004, 52, 1-26.
167. Remillard, S.; Rebhun, L.I.; Howie, G.A.; Kupchan, S.M. Antimitotic activity of the potent tumor inhibitor maytansine. Science, 1975, 189, 1002-1005.